At week 361
- More patients achieved sustained remission with DUPIXENT + oral corticosteroid (OCS) taper vs placebo + OCS taper (18% vs 6%; primary endpoint; 95% CI: 12.2% [-0.8, 26.1])a
- Clinically meaningful itch improvement in 38% vs 11% of patients, respectively (secondary endpoint; 95% CI: 27.8% [11.6, 43.4])b
- Median cumulative dose of OCS at Week 36 was 2.8 g in patients treated with DUPIXENT vs 4.1 g with placebo
aThis data analysis for the primary endpoint did not meet statistical significance.
bDefinitive conclusions cannot be made for these results. Data were not multiplicity controlled.
DUPIXENT has a demonstrated
long-term safety profile THROUGH WEEK 521,c
Most common adverse reactions (incidence ≥2%) in patients with bullous pemphigoid are arthralgia, conjunctivitis, vision blurred,
herpes viral infections, and keratitis.
A case of acute generalized exanthematous pustulosis (AGEP) was reported in 1 subject with bullous pemphigoid treated with DUPIXENT compared with 0 subjects in the placebo group.
cAt the time of safety analysis, 87 subjects had completed Week 36 and 65 subjects had completed Week 52.
prescribed biologic
by dermatologists2,d
MORE THAN 1 MILLION
PATIENTS
on therapy across approved
indications worldwide2,e
AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; EoE, eosinophilic esophagitis; PN, prurigo nodularis.
dIQVIA SMART Portal Patient Insights as of March 2025.
eThis worldwide number is largely comprised from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the rest of the world comprising ≈10% of this number. This number is comprised of the following US approved indications: AD, asthma, COPD, CRSwNP, PN, and EoE. Data through February 2025.
DO YOU HAVE PATIENTS WHO
MAY BE READY FOR DUPIXENT?